Exact Sciences Corporation has announced that its Oncodetect™ molecular residual disease $(MRD.AU)$ test has received Medicare coverage through the Centers for Medicare & Medicaid Services' $(CMS)$ Molecular Diagnostic Services Program (MolDX). This coverage is for serial use in patients with stage II, III, and resectable stage IV colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period. This approval is a significant milestone in Exact Sciences' mission to enhance cancer treatment through earlier detection and personalized care. The Oncodetect test, which tracks up to 200 ctDNA variants, has demonstrated its prognostic power in robust clinical validation studies and can detect signs of cancer recurrence up to two years earlier than imaging alone. This development underscores the clinical value of the MRD test and reinforces Exact Sciences' leadership in advancing oncology diagnostic tools.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。